| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2025-01-22 | 2027-06 | 2027-03 |
| NCT05186753 | (Summit) a Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients with Indolent or Smoldering Systemic Mastocytosis | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-06-27 | 2030-04 | 2025-09 |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-04-14 | 2026-09 | 2025-07 |
| NCT04996875 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | RECRUITING | PHASE2 | 2021-11-09 | 2026-07 | 2025-09 |
| NCT03680560 | Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | TERMINATED | PHASE1 | 2019-03-13 | 2020-03-12 | 2020-03-12 |
| NCT03266692 | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | TERMINATED | PHASE1 | 2018-02-22 | 2019-10-01 | 2019-10-01 |
| NCT03189836 | Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | TERMINATED | PHASE1 | 2017-10-04 | 2020-09-21 | 2020-09-21 |
| NCT02776813 | Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma | COMPLETED | PHASE1 | 2016-08 | 2020-02-12 | 2020-02-12 |
| NCT02401815 | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2015-03-06 | 2020-05-11 | 2020-05-11 |